Immix Biopharma Investor Presentation Deck

N-GENIUS Platform: EXPAND Technology + COBRA Binder (1/2) All BCMA CAR-Ts Are Not Created Equal FIM 3 Key Elements Purpose-Built Cell Therapy Evidence Capture Engine + Relational Database Relating ImmixBio internal data to external to accelerate therapy design, manufacture, and preclinical Proprietary EXPAND technology Applied to multiple cell therapy indications, already utilized to create NXC-201, to potentially increase efficacy and tolerability Atomized, Novel Binding Scaffold Generation Engine Allows us to make the correct binding for every molecule Source: Aherie, N., et al Haematologica. 2022 N-GENIUS PLATFORM CD3Z CD3Zy 4-1BB 4-1BB Produced NXC-201 CD8 Transmembrane Protein Abecma (reference) CD8 Transmembrane Protein CD8 Hinge NXC-201 EXPAND Technology + COBRA Binder CD8 Hinge Tumor Binding Domain ●●● IMMİX S BIOPHARMA COBRA Binder CD8 Signaling Protein CD8 Signaling Protein EXPAND Technology + COBRA Binder Modifications 9

View entire presentation